In patients with IBS, Piezo2 expression in the colon significantly correlates with visceral sensitivity, indicating that Piezo2 is a candidate biomarker for visceral hypersensitivity in IBS (Bai et al., 2017). Here, PIEZO2 is linked to irritable bowel syndrome.